As the PI3K/AKT pathway is one of the most commonly dysregulated pathways in cancer [53], future work will investigate whether ASAP1 overexpression can activate AKT signaling in cancer cells, and whether this impacts on the treatment of tumor patients with amplified or overexpressed ASAP1. Here, ASAP1 is linked to cancer.